
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RSV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Anima Research Center Participating In A Trial For An Investigational RSV Vaccine
Details : Anima is collaborating with the U.S. pharmaceutical company Moderna, among others, to evaluate an RSV vaccine under development, aimed at persons over 60 years of age.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : RSV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $2,420.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $120.0 million
March 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $2,420.0 million
Deal Type : Collaboration
